Therapies that involve the use of biological products (cells, tissues, genes or antibodies) aiming to generate a positive impact on the lives of patients with complex pathologies whose treatment – and cures – have not yet been established. In addition to involving biological products, such therapies are often personalized for each patient, further characterizing these therapies as advanced.

They are based on modifying the patient's cells, genes or tissues, aiming to correct what is causing the pathology. To achieve this, artificial intelligence and bioinformatics techniques are used to understand how proteins, enzymes, genes and other molecules interact and contribute to the development of a given pathology. Thus, it is possible to modify cells and use them as a therapeutic agent (cell therapy); identify genes that are targets for use in the treatment of a given disease (gene therapy) in addition to assisting in the development of molecules that can be used both in the diagnosis and treatment of a pathology (theranostics).

Currently, with the increase in the population's longevity, we see an increase in the number of patients with different neurodegenerative diseases (such as Alzheimer's and multiple sclerosis), who still do not have a premature diagnosis or treatments that can actually mitigate the disease. In the same direction, the incidence and diagnosis of cancer is increasing, whether in adults, the elderly and children. Each cancer responds differently to existing treatments. Therefore, researching and developing more efficient and personalized treatments impacts their quality of life. Last but not least, rare diseases have a significant incidence, mainly affecting children and requiring the development of diagnostic treatments.